Abstract: Methods, systems, and computer readable storage media relate to processing and analyzing a sample to determine presence or concentration of at least one sensor target in a sample. A method of quantifying a sample using a sensor may include obtaining sensor data, the sensor data including in-situ calibration data from a housekeeping protein; analyzing the sensor data; and outputting results of the analyzing. The method may be used with a system that includes a sensing device and a module. The system may also include an analysis device that can be in communication with the sensing device.

Abstract: This disclosure relates biomarkers of cancer, e.g. prostate cancer. The biomarkers may be altered expression of nucleic acids, mutations, or proteins encoded therefrom. In certain embodiments, the disclosure relates to methods for diagnosing prostate cancer, methods of distinguishing between less aggressive and high aggressive prostate cancer, methods of determining predisposition to recurrence of prostate cancer, methods of monitoring progression/regression of prostate cancer, methods of assessing efficacy of compositions for treating prostate cancer, and methods of screening compositions for activity in modulating biomarkers of prostate cancer.

Abstract: Methods, systems, and computer readable storage media relate to processing and analyzing a sample to determine presence or concentration of at least one sensor target in a sample. A method of quantifying a sample using a sensor may include obtaining sensor data, the sensor data including in-situ calibration data from a housekeeping protein; analyzing the sensor data; and outputting results of the analyzing. The method may be used with a system that includes a sensing device and a module. The system may also include an analysis device that can be in communication with the sensing device.

Abstract: This disclosure relates biomarkers of cancer, e.g. prostate cancer. The biomarkers may be altered expression of nucleic acids, mutations, or proteins encoded therefrom. In certain embodiments, the disclosure relates to methods for diagnosing pro-state cancer, methods of distinguishing between less aggressive and high aggressive prostate cancer, methods of determining predisposition to recurrence of prostate cancer, methods of monitoring progression/regression of prostate cancer, methods of assessing efficacy of compositions for treating prostate cancer, and methods of screening compositions for activity in modulating biomarkers of prostate cancer.